GlassScriptPhysician profile
Stephen James Lightfield
NPI 1659004810
$1,704.44
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $483 · 2023: $922 · 2024: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,221.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $509.52 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $345.76 | 2022-2024 | Xifaxan, Trulance |
| Ironwood Pharmaceuticals, INC | $145.30 | 2023-2024 | Linzess |
| Genzyme Corporation | $143.98 | 2022-2024 | |
| Celgene Corporation | $111.88 | 2022-2023 | Zeposia |
| Pfizer INC. | $87.81 | 2023 | |
| Ferring Pharmaceuticals INC. | $81.87 | 2022-2024 | Rebyota, Clenpiq |
| Qol Medical, LLC | $62.85 | 2022-2023 | Sucraid |
| Regeneron Healthcare Solutions, INC. | $36.58 | 2022 | |
| Merck Sharp & Dohme LLC | $32.71 | 2023-2024 | Dificid |
| Phathom Pharmaceuticals, INC. | $31.19 | 2024 | Voquezna |
| Pharmacosmos Therapeutics INC. | $24.08 | 2022 | |
| Nestle Healthcare Nutrition INC. | $23.77 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.66 | 2023 | Entyvio |
| Janssen Biotech, INC. | $17.18 | 2024 | Stelara |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $16.84 | 2023 | Terlivaz |
| Organon LLC | $14.46 | 2023 | Renflexis, Hadlima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Lightfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.